Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

Tolaney S. M., Cicin I., Betancourt R., Chan A., Kaen D., Kaufman P. A., ...Daha Fazla

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri) identifier

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 38
  • Basıldığı Ülke: ELECTR NETWORK
  • Trakya Üniversitesi Adresli: Evet